These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29133033)

  • 1. Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant.
    Fukuda T; Umeki T; Tokushima K; Xiang G; Yoshida Y; Ishibashi F; Oku Y; Nishiya N; Uehara Y; Iwao M
    Bioorg Med Chem; 2017 Dec; 25(24):6563-6580. PubMed ID: 29133033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of azalamellarin N and its A-ring-modified analogues as non-covalent inhibitors of the EGFR T790M/L858R mutant.
    Fukuda T; Anzai M; Nakahara A; Yamashita K; Matsukura K; Ishibashi F; Oku Y; Nishiya N; Uehara Y; Iwao M
    Bioorg Med Chem; 2021 Mar; 34():116039. PubMed ID: 33556869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
    Yan Q; Chen Y; Tang B; Xiao Q; Qu R; Tong L; Liu J; Ding J; Chen Y; Ding N; Tan W; Xie H; Li Y
    Eur J Med Chem; 2018 May; 152():298-306. PubMed ID: 29730192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
    Qin X; Li Z; Yang L; Liu P; Hu L; Zeng C; Pan Z
    Bioorg Med Chem; 2016 Jul; 24(13):2871-2881. PubMed ID: 27234887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of selective EGFR modulator to inhibit L858R/T790M double mutants bearing a N-9-Diphenyl-9H-purin-2-amine scaffold.
    Hu J; Han Y; Wang J; Liu Y; Zhao Y; Liu Y; Gong P
    Bioorg Med Chem; 2018 May; 26(8):1810-1822. PubMed ID: 29486953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
    Xiao Q; Qu R; Gao D; Yan Q; Tong L; Zhang W; Ding J; Xie H; Li Y
    Bioorg Med Chem; 2016 Jun; 24(12):2673-80. PubMed ID: 27131639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors.
    Song Z; Jin Y; Ge Y; Wang C; Zhang J; Tang Z; Peng J; Liu K; Li Y; Ma X
    Bioorg Med Chem; 2016 Nov; 24(21):5505-5512. PubMed ID: 27634676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant.
    Günther M; Juchum M; Kelter G; Fiebig H; Laufer S
    Angew Chem Int Ed Engl; 2016 Aug; 55(36):10890-4. PubMed ID: 27466205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Zhang M; Wang Y; Wang J; Liu Z; Shi J; Li M; Zhu Y; Wang S
    Chem Pharm Bull (Tokyo); 2020; 68(10):971-980. PubMed ID: 32999149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
    Qin M; Wang T; Xu B; Ma Z; Jiang N; Xie H; Gong P; Zhao Y
    Eur J Med Chem; 2015 Nov; 104():115-26. PubMed ID: 26451770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
    Hao Y; Wang X; Zhang T; Sun D; Tong Y; Xu Y; Chen H; Tong L; Zhu L; Zhao Z; Chen Z; Ding J; Xie H; Xu Y; Li H
    J Med Chem; 2016 Aug; 59(15):7111-24. PubMed ID: 27396610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor.
    Nishiya N; Oku Y; Ishikawa C; Fukuda T; Dan S; Mashima T; Ushijima M; Furukawa Y; Sasaki Y; Otsu K; Sakyo T; Abe M; Yonezawa H; Ishibashi F; Matsuura M; Tomida A; Seimiya H; Yamori T; Iwao M; Uehara Y
    Cancer Sci; 2021 May; 112(5):1963-1974. PubMed ID: 33544933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
    Zhou W; Liu X; Tu Z; Zhang L; Ku X; Bai F; Zhao Z; Xu Y; Ding K; Li H
    J Med Chem; 2013 Oct; 56(20):7821-37. PubMed ID: 24053674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
    Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
    Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Makino A; Miyazaki A; Tomoike A; Kimura H; Arimitsu K; Hirata M; Ohmomo Y; Nishii R; Okazawa H; Kiyono Y; Ono M; Saji H
    Bioorg Med Chem; 2018 May; 26(8):1609-1613. PubMed ID: 29478801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
    Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
    J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation.
    Su Z; Yang T; Wang J; Lai M; Tong L; Wumaier G; Chen Z; Li S; Li H; Xie H; Zhao Z
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127327. PubMed ID: 32631532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
    Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
    Patel HM; Pawara R; Ansari A; Noolvi M; Surana S
    Bioorg Med Chem; 2017 May; 25(10):2713-2723. PubMed ID: 28366268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.